Recombinant Human VEGFR1/Flt-1 Fc Chimera Protein

Formulations:
Catalog # Availability Size / Price Qty
321-FL-050
Product Details
Citations (36)
FAQs
Reviews (11)

Recombinant Human VEGFR1/Flt-1 Fc Chimera Protein Summary

Purity
>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
Activity
Measured by its ability to inhibit the VEGF-dependent proliferation of HUVEC human umbilical vein endothelial cells. Conn, G. et al. (1990) Proc. Natl. Acad. Sci. USA 87:1323. The ED50 for this effect is 5-30 ng/mL.
Source
Spodoptera frugiperda, Sf 21 (baculovirus)-derived human VEGFR1/Flt-1 protein
Human VEGFR1
(Ser27-His687)
Accession # AAC50060
IEGRMD Human IgG1
(Pro100-Lys330)
6-His tag
N-terminus C-terminus
Accession #
N-terminal Sequence
Analysis
Ser27
Structure / Form
Disulfide-linked homodimer
Predicted Molecular Mass
100 kDa (monomer)
SDS-PAGE
123 kDa, reducing conditions

Product Datasheets

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

321-FL

Formulation Lyophilized from a 0.2 μm filtered solution in MOPS, NaCl and CHAPS with BSA as a carrier protein.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 3 months, 2 to 8 °C under sterile conditions after reconstitution.

321-FL/CF

Formulation Lyophilized from a 0.2 μm filtered solution in MOPS, NaCl and CHAPS.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 3 months, 2 to 8 °C under sterile conditions after reconstitution.
Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: VEGFR1/Flt-1

VEGFR1 (vascular endothelial growth factor receptor 1), also called Flt-1 (Fms-like tyrosine kinase), is a 180 kDa type I transmembrane glycoprotein in the class III subfamily of receptor tyrosine kinases (RTKs) (1, 2). While family members VEGFR1, VEGFR2/KDR/Flk-1 and VEGFR3/Flt-4 are all mainly expressed on endothelial cells and play central roles in vasculogenesis, angiogenesis, and lymphangiogenesis, only VEGFR1 is expressed on macrophages, and mainly plays inhibitory roles (1-3). VEGFR1 expression is also reported on osteoblasts, placental trophoblasts, renal mesangial cells, and some hematopoietic stem cells (1, 2). Like other class III RTKs, human VEGFR1 contains a signal peptide (aa 1-22), an extracellular domain (ECD aa 27-758) with seven Ig-like repeats, a transmembrane domain (aa 759-780) and a cytoplasmic region (aa 781-1338) with a tyrosine kinase domain and several autocatalytic phosphotyrosine sites. Human VEGFR1 ECD shares 78%, 78%, 84%, 87%, and 90% aa sequence identity with mouse, rat, porcine, canine and equine VEGFR1, respectively. Soluble forms of the VEGFR1 ECD are produced by alternative splicing, and may also be shed during regulated intracellular proteolysis (4-10). Both soluble and transmembrane forms can inhibit angiogenesis by binding and sequestering its ligands, VEGF (VEGF-A), VEGF-B or PlGF (6‑11). VEGFR1 dimerizes upon ligand binding, which can include heterodimerization with VEGFR2 that modifies VEGFR2-mediated endothelial proliferation and vessel branching (8, 11, 12). VEGFR1 binds VEGF with higher affinity than does VEGFR2, but shows weaker kinase activity (9, 13). Both PlGF and VEGF induce autophosphorylation of transmembrane VEGFR1 (5, 9, 13). While deletion of mouse VEGFR1 is lethal due to overgrowth and disorganization of the vasculature, kinase-inactive mutants are viable (13, 14). VEGFR1 is up‑regulated during hypoxia, and participates in neovascularization and wound healing (1, 2, 15). VEGFR1 engagement on monocyte/macrophage lineage cells enhances their migration, and release of growth factors and cytokines (1, 3, 13, 16). Lymphangiogenesis, angiogenesis, and growth-promoting effects of VEGFR1 are thought to result from enhanced migration of macrophages from the bone marrow to tumors and tissues where they recruit endothelial progenitors (3, 16). Circulating levels of VEGFR1 increase during pregnancy and are further elevated in preeclampsia (4, 6, 17).

References
  1. Otrock, Z.K. et al. (2007) Blood Cells Mol. Dis. 38:258.
  2. Peters, K.G. et al. (1993) Proc. Natl. Acad. Sci. USA 90:8915.
  3. Murakami, M. et al. (2008) Arterioscler. Thromb. Vasc. Biol. 28:658.
  4. Al-Ani, B. et al. (2010) Hypertension 55:689.
  5. Rahimi, N. et al. (2009) Cancer Res. 69:2607.
  6. He, Y. et al. (1999) Molecular Endocrinology 13:537.
  7. Cai, J. et al. (2012) EMBO Mol. Med. 4:980.
  8. Kendall, R.L. and K.A. Thomas (1993) Proc. Natl. Acad. Sci. USA 90:10705.
  9. Sawano, A. et al. (1996) Cell Growth Differ. 7:213.
  10. Barleon, B. et al. (1997) J. Biol. Chem. 272:10382.
  11. Kappas, N.C. et al. (2008) J. Cell Biol. 181:847.
  12. Mac Gabhann, F. and A.S. Popel (2007) Biophys. Chem. 128:125.
  13. Hiratsuka, S. et al. (1998) Proc. Natl. Acad. Sci. USA 95:9349.
  14. Fong, G.H. et al. (1995) Nature 376:66.
  15. Nishi, J. et al. (2008) Circ. Res. 103:261.
  16. Muramatsu, M. et al. (2010) Cancer Res. 70:8211.
  17. Levine, R.J. et al. (2004) N. Engl. J. Med. 350:672.
Long Name
Vascular Endothelial Growth Factor Receptor 1
Entrez Gene IDs
2321 (Human); 14254 (Mouse)
Alternate Names
EC 2.7.10; EC 2.7.10.1; FLT; FLT1; Flt-1; Fms-like tyrosine kinase 1; fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascularpermeability factor receptor); FRT; Tyrosine-protein kinase FRT; Tyrosine-protein kinase receptor FLT; vascular endothelial growth factor receptor 1; Vascular permeability factor receptor; VEGF R1; VEGFR1; VEGFR-1

Citations for Recombinant Human VEGFR1/Flt-1 Fc Chimera Protein

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

36 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Calcium dobesilate reduces VEGF signaling by interfering with heparan sulfate binding site and protects from vascular complications in diabetic mice
    Authors: F Njau, N Shushakova, H Schenk, VC Wulfmeyer, R Bollin, J Menne, H Haller
    PLoS ONE, 2020;15(1):e0218494.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  2. Inhibition of FLT1 ameliorates muscular dystrophy phenotype by increased vasculature in a mouse model of Duchenne muscular dystrophy
    Authors: M Verma, Y Shimizu-Mo, Y Asakura, JP Ennen, J Bosco, Z Zhou, GH Fong, S Josiah, D Keefe, A Asakura
    PLoS Genet., 2019;15(12):e1008468.
    Species: Mouse
    Sample Types:
    Applications: Surface Plasmon Resonance
  3. Hypoxia Induced Heparan Sulfate Primes the Extracellular Matrix for Endothelial Cell Recruitment by Facilitating VEGF-Fibronectin Interactions
    Authors: JA Buczek-Tho, CB Rich, MA Nugent
    Int J Mol Sci, 2019;20(20):.
    Species: Human
    Sample Types: Recombinant Protein
    Applications: Bioassay
  4. VEGF may contribute to macrophage recruitment and M2 polarization in the decidua
    Authors: KC Wheeler, MK Jena, BS Pradhan, N Nayak, S Das, CD Hsu, DS Wheeler, K Chen, NR Nayak
    PLoS ONE, 2018;13(1):e0191040.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  5. Muscle Satellite Cell Cross-Talk with a Vascular Niche Maintains Quiescence via VEGF and Notch Signaling
    Authors: M Verma, Y Asakura, BSR Murakonda, T Pengo, C Latroche, B Chazaud, LK McLoon, A Asakura
    Cell Stem Cell, 2018;23(4):530-543.e9.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  6. Dysregulation of the Fas/FasL system in an experimental animal model of HELLP syndrome
    Authors: J Gibbens, R Morris, T Bowles, SK Spencer, K Wallace
    Pregnancy Hypertens, 2017;8(0):26-30.
    Species: Rat
    Sample Types: In Vivo
    Applications: In Vivo
  7. Snake venom VEGF Vammin induces a highly efficient angiogenic response in skeletal muscle via VEGFR-2/NRP specific signaling
    Authors: PI Toivanen, T Nieminen, JP Laakkonen, T Heikura, MU Kaikkonen, S Ylä-Herttu
    Sci Rep, 2017;7(1):5525.
    Species: Human
    Sample Types: Recombinant Protein
    Applications: Bioassay
  8. Discovery of High-Affinity PDGF-VEGFR Interactions: Redefining RTK Dynamics
    Authors: SB Mamer, S Chen, JC Weddell, A Palasz, A Wittenkell, M Kumar, PI Imoukhuede
    Sci Rep, 2017;7(1):16439.
    Species: Human
    Sample Types: Recombinant Protein
    Applications: Surface Plasmon Resonance
  9. Secretogranin III as a disease-associated ligand for antiangiogenic therapy of diabetic retinopathy
    Authors: ME LeBlanc, W Wang, X Chen, NB Caberoy, F Guo, C Shen, Y Ji, H Tian, H Wang, R Chen, W Li
    J. Exp. Med, 2017;0(0):.
    Applications: Bioassay
  10. Axitinib Has Antiangiogenic and Antitumorigenic Activity in Myxoid Liposarcoma
    Authors: Terrance G Johns
    Sarcoma, 2016;2016(0):3484673.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  11. Adsorption as a Contributor for Inflammatory Mediators Removal by Different Hemofiltration Membranes: A Pilot Study
    Authors: Benjamin Malard
    Artif Organs, 2016;0(0):.
    Species: Human
    Sample Types: Plasma
    Applications: Hemofiltration Procedure
  12. Tumor-Derived Factors and Reduced p53 Promote Endothelial Cell Centrosome Over-Duplication
    PLoS ONE, 2016;11(12):e0168334.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  13. Proangiogenic Interactions of Vascular Endothelial MMP14 With VEGF Receptor 1 in VEGFA-Mediated Corneal Angiogenesis.
    Authors: Kyu-Yeon Han, Jin-Hong Chang, Hyun Lee, Dimitri T Azar
    Investigative Ophthalmology & Visual Science, 2016;0(0):1552-5783.
    Species: Human
    Sample Types: Recombinant Protein
    Applications: Enzyme Assay
  14. Synergistic Binding of Vascular Endothelial Growth Factor-A and Its Receptors to Heparin Selectively Modulates Complex Affinity.
    Authors: Teran M, Nugent M
    J Biol Chem, 2015;290(26):16451-62.
    Species: Human
    Sample Types: Protein
    Applications: Bioassay
  15. Endothelial cell adhesion to soluble vascular endothelial growth factor receptor-1 triggers a cell dynamic and angiogenic phenotype.
    Authors: Orecchia A, Mettouchi A, Uva P, Simon G, Arcelli D, Avitabile S, Ragone G, Meneguzzi G, Pfenninger K, Zambruno G, Failla C
    FASEB J, 2014;28(2):692-704.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  16. Effects of sFlt-1 and alpha 2-macroglobulin on vascular endothelial growth factor-induced endothelin-1 upregulation in human microvascular endothelial cells.
    Authors: Yi K, Jung S, Cho G, Seol H, Hong S, Oh M, Kim H
    Placenta, 2014;35(1):64-9.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  17. Tissue inhibitor of metalloproteinases-3 peptides inhibit angiogenesis and choroidal neovascularization in mice.
    Authors: Qi, Jian Hua, Ebrahem, Quteba, Ali, Mariya, Cutler, Alecia, Bell, Brent, Prayson, Nicholas, Sears, Jonathan, Knauper, Vera, Murphy, Gillian, Anand-Apte, Bela
    PLoS ONE, 2013;8(3):e55667.
    Species: Human
    Sample Types: Recombinant Protein
    Applications: Competitive ELISA
  18. The adaptation of the blood-brain barrier to vascular endothelial growth factor and placental growth factor during pregnancy.
    Authors: Schreurs MP, Houston EM, May V, Cipolla MJ
    FASEB J., 2012;26(1):355-62.
    Species: Rat
    Sample Types: In Vivo
    Applications: In Vivo
  19. Cytomegalovirus impairs cytotrophoblast-induced lymphangiogenesis and vascular remodeling in an in vivo human placentation model.
    Authors: Tabata T, Petitt M, Fang-Hoover J, Rivera J, Nozawa N, Shiboski S, Inoue N, Pereira L
    Am J Pathol, 2012;181(5):1540-59.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  20. Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression.
    Authors: Franco M, Roswall P, Cortez E, Hanahan D, Pietras K
    Blood, 2011;118(10):2906-17.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  21. Endorepellin, the angiostatic module of perlecan, interacts with both the alpha2beta1 integrin and vascular endothelial growth factor receptor 2 (VEGFR2): a dual receptor antagonism.
    Authors: Goyal A, Pal N, Concannon M, Paul M, Doran M, Poluzzi C, Sekiguchi K, Whitelock JM, Neill T, Iozzo RV
    J. Biol. Chem., 2011;286(29):25947-62.
    Species: Human
    Sample Types: Recombinant Protein
    Applications: Binding Assay
  22. Regulation of pathologic retinal angiogenesis in mice and inhibition of VEGF-VEGFR2 binding by soluble heparan sulfate.
    Authors: Nishiguchi KM, Kataoka K, Kachi S
    PLoS ONE, 2010;5(10):e13493.
    Species: Porcine
    Sample Types: Aqueous Humor
    Applications: Bioassay
  23. Soluble forms of VEGF receptor-1 and -2 promote vascular maturation via mural cell recruitment.
    Authors: Lorquet S, Berndt S, Blacher S, Gengoux E, Peulen O, Maquoi E, Noel A, Foidart JM, Munaut C, Pequeux C
    FASEB J., 2010;24(10):3782-95.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  24. VEGF(121)b, a new member of the VEGF(xxx)b family of VEGF-A splice isoforms, inhibits neovascularisation and tumour growth in vivo.
    Authors: Rennel ES, Varey AH, Churchill AJ, Wheatley ER, Stewart L, Mather S, Bates DO, Harper SJ
    Br. J. Cancer, 2009;101(7):1183-93.
    Species: Human
    Sample Types: Recombinant Protein
    Applications: Bioassay
  25. Expression of soluble vascular endothelial growth factor receptor-1 in human monocyte-derived mature dendritic cells contributes to their antiangiogenic property.
    Authors: Kishuku M, Nishioka Y, Abe S, Kishi J, Ogino H, Aono Y, Azuma M, Kinoshita K, Batmunkh R, Rentsenhand B, Makino H, Ranjan P, Minakuchi K, Sone S
    J. Immunol., 2009;183(12):8176-85.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  26. Modulation of angiogenesis by a tetrameric tripeptide that antagonizes vascular endothelial growth factor receptor 1.
    Authors: Ponticelli S, Marasco D, Tarallo V, Albuquerque RJ, Mitola S, Takeda A, Stassen JM, Presta M, Ambati J, Ruvo M, De Falco S
    J. Biol. Chem., 2008;283(49):34250-9.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  27. Cytotrophoblast induction of arterial apoptosis and lymphangiogenesis in an in vivo model of human placentation.
    Authors: Red-Horse K, Rivera J, Schanz A, Zhou Y, Winn V, Kapidzic M, Maltepe E, Okazaki K, Kochman R, Vo KC, Giudice L, Erlebacher A, McCune JM, Stoddart CA, Fisher SJ
    J. Clin. Invest., 2006;116(10):2643-52.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  28. Low molecular weight fucoidan increases VEGF165-induced endothelial cell migration by enhancing VEGF165 binding to VEGFR-2 and NRP1.
    Authors: Lake AC, Vassy R, Di Benedetto M, Lavigne D, Le Visage C, Perret GY, Letourneur D
    J. Biol. Chem., 2006;281(49):37844-52.
    Species: Human
    Sample Types: Buffer
    Applications: Bioassay
  29. Ligand-induced internalization selects use of common receptor neuropilin-1 by VEGF165 and semaphorin3A.
    Authors: Narazaki M, Tosato G
    Blood, 2006;107(10):3892-901.
    Species: N/A
    Sample Types: N/A
    Applications: ELISA (Standard)
  30. Intraovarian actions of anti-angiogenic agents disrupt periovulatory events during the menstrual cycle in monkeys.
    Authors: Xu F, Hazzard TM, Evans A, Charnock-Jones S, Smith S, Stouffer RL
    Contraception, 2005;71(4):239-48.
    Species: Primate - Macaca mulatta (Rhesus Macaque)
    Sample Types: In Vivo
    Applications: In Vivo
  31. Estrogen regulates the production of VEGF for osteoclast formation and activity in op/op mice.
    Authors: Kodama I, Sanada M, Yoshiko Y, Tsuda M, Ohama K
    J. Bone Miner. Res., 2004;19(2):200-6.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  32. Estrogen enhances angiogenesis through a pathway involving platelet-activating factor-mediated nuclear factor-kappaB activation.
    Authors: Seo KH, Lee HS, Jung B, Ko HM, Choi JH, Park SJ, Choi IH, Lee HK, Im SY
    Cancer Res., 2004;64(18):6482-8.
    Species: Porcine
    Sample Types: Whole Cells
    Applications: Bioassay
  33. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.
    Authors: Maynard SE, Min JY, Merchan J, Lim KH, Mondal S, Stillman IE, Epstein FH, Karumanchi SA
    J. Clin. Invest., 2003;111(5):649-58.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  34. Plasma angiopoietin-1, angiopoietin-2 and Tie-2 in breast and prostate cancer: a comparison with VEGF and Flt-1.
    Authors: Caine GJ, Blann AD, Stonelake PS, Ryan P, Lip GY
    Eur. J. Clin. Invest., 2003;33(10):883-90.
    Species: N/A
    Sample Types: N/A
    Applications: ELISA (Standard)
  35. VEGF signaling is required for the assembly but not the maintenance of embryonic blood vessels.
    Authors: Argraves WS, Larue AC, Fleming PA, Drake CJ
    Dev. Dyn., 2002;225(3):298-304.
    Species: Avian - Quail
    Sample Types: Whole Tissue
    Applications: Bioassay
  36. Steps toward mapping the human vasculature by phage display.
    Authors: Arap W, Kolonin MG, Trepel M, Lahdenranta J, Cardo-Vila M, Giordano RJ, Mintz PJ, Ardelt PU, Yao VJ, Vidal CI, Chen L, Flamm A, Valtanen H, Weavind LM, Hicks ME, Pollock RE, Botz GH, Bucana CD, Koivunen E, Cahill D, Troncoso P, Baggerly KA, Pentz RD, Do KA, Logothetis CJ, Pasqualini R
    Nat. Med., 2002;8(2):121-7.
    Species: Human
    Sample Types: Buffer
    Applications: Binding Assay

FAQs

  1. Can Recombinant Human VEGF R1/Flt-1 Fc Chimera (Catalog # 321-FL) block the activity of Mouse VEGF?
    • Yes. In our testing of HUVECs, catalog # 321-FL blocks recombinant mouse VEGF as well as it blocks recombinant human VEGF.

View all Proteins and Enzyme FAQs

Reviews for Recombinant Human VEGFR1/Flt-1 Fc Chimera Protein

Average Rating: 4.8 (Based on 11 Reviews)

5 Star
90.91%
4 Star
0%
3 Star
9.09%
2 Star
0%
1 Star
0%

Have you used Recombinant Human VEGFR1/Flt-1 Fc Chimera Protein?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Recombinant Human VEGFR1/Flt-1 Fc Chimera Protein
By Anonymous on 08/05/2020
Application: Co-immunoprecipitation study

Recombinant Human VEGF R1/Flt-1 Fc Chimera Protein
By Anonymous on 04/12/2018
Application: SDS-PAGE Control

Recombinant Human VEGF R1/Flt-1 Fc Chimera Protein
By Anonymous on 03/30/2018
Application: Binding assay/Protein-protein interaction

Recombinant Human VEGF R1/Flt-1 Fc Chimera Protein
By Anonymous on 03/15/2018
Application: SDS-PAGE Control

Recombinant Human VEGF R1/Flt-1 Fc Chimera Protein
By Anonymous on 03/11/2018
Application: SDS-PAGE Control

Recombinant Human VEGF R1/Flt-1 Fc Chimera Protein
By Anonymous on 11/27/2017
Application: Binding assay/Protein-protein interaction

Recombinant Human VEGF R1/Flt-1 Fc Chimera Protein
By Anonymous on 11/18/2017
Application: Binding assay/Protein-protein interaction

Recombinant Human VEGF R1/Flt-1 Fc Chimera Protein
By Anonymous on 11/10/2017
Application: In vitro bioactivity in cell culture

Recombinant Human VEGF R1/Flt-1 Fc Chimera Protein
By Anonymous on 10/23/2017
Application: Surface plasma resonance

Recombinant Human VEGF R1/Flt-1 Fc Chimera Protein
By Anonymous on 07/29/2017
Application: Immunoassay Standard

Recombinant Human VEGF R1/Flt-1 Fc Chimera Protein
By Anonymous on 07/29/2017
Application: Binding assay/Protein-protein interaction